Today, for your business to succeed, it needs to stay competitive. The medical line needs to innovate new technology that can give good results and great benefit. Without techniques to analyze the scientific world, the game, and how the company can innovate, it stagnates. As medical advances at a rapid pace, a Hospital needs to be able to utilize that technology with innovative concepts. Companies can fail if they can’t grow in this ever-changing world. Innovation is the only way to make a destination statement in the biotech world and continuously gives a newly invented tool on top gear. The long-term strategy of a company is then one of the most critical aspects of the medical world. By developing strategies to stay competitive, the industry has a better chance to succeed.
Transmural Biotech is a group of creative, young, and talented engineers. The main field of expertise in Transmural Biotech has focused on the application of Imaging Processing Techniques to the development of Medical Technologies, correctly oriented to the development of automatic diagnosis tools for complex pathologies. The experienced team has engaged with young talented, and highly encouraged engineers with tremendous academic scores. Most of them are developing their Ph.D. work in Transmural Biotech in a long-term relationship with the pointed Universities settled in Barcelona.
Transmural Biotech was born in 2009 in the hospital clinic university of Barcelona as a spin-off innovation first time. In a short period, it becomes a consolidated company that innovates the artificial intelligence to maternal-fetal health. Miguel Ángel Lorente and David Fernandez are the CEOs of the company. They genuinely believe in scientific innovation, which is working as a passionate team of Transmural Biotech. Transmural Biotech is a work in Quantus FLM (fetal lung maturity test) that has based on ultrasound images, and Quantus PREMATURITY is an application to understand the hazard of spontaneous premature birth early.